Jeffrey B. Kindler
Fund Advisor @ Israel Biotech Fund
New York, United States
Jeffrey B. Kindler is a seed investor at Israel Biotech Fund in New York focused on Health Care and Medical Device. Jeff Kindler is the CEO of Centrexion Therapeutics. He brings more than three decades of business experience and has held leadership positions at some of the world’s most recognized companies. Jeff is also executive chair of vTv Therapeutics, venture partner at Lux Capital, managing director at Starboard Capital and the global chair for the GLGInstitute. Prior to joining Centrexion, Jeff was the chairman and CEO of Pfizer, the world’s largest research-based biopharmaceutical company. As CEO, he led Pfizer’s $68 billion merger and acquisition of Wyeth, diversified its product portfolio, improved its research and development pipeline, and reshaped the company’s commercial, innovation and leadership models to drive growth and cultural change. Earlier in his career, Jeff served as the executive vice president and general counsel for McDonald’s Corporation and was the vice president of litigation and legal policy for the General Electric Company. Prior to GE, Jeff practiced civil and criminal litigation as a Partner of William & Connolly. Jeff holds a B.A. from Tufts University and a J.D. from Harvard University.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Jeffrey B. Kindler invests in
Stages Jeffrey B. Kindler invests in
Countries Jeffrey B. Kindler invests in
Investment Focus
Industry
- Health Care 2 (67%)
- Medical Device 2 (67%)
- Clinical Trials 2 (67%)
- Medical 1 (33%)
- Hardware 1 (33%)
Stage
- Seed 2 (67%)
- Series D 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Power Life Science
|
Power Life Science believes that every patient deserves the chance to participate in a life-changing clinical trial. Is backed by some of the best healthcare investors and operators with a range of experience across clinical research and biopharmaceuticals. We are a small team - each of us with our own personal story and motivation to make adifference in the lives of patients. | $7M / Seed / Aug 30, 2022 | |
Medable
|
Medable provides a global decentralized trial platform that streamlines design, recruitment, retention, and data quality, replacing siloed systems with integrated digital tools, data, and interfaces to accelerate trial execution. The platform connects patients, sites, and clinical trial teams to improve patient access, experience, and outcomes. Itis now used by leading biopharma sponsors and clinical research organizations worldwide and has been used for trials in 30+ countries and 26 languages.It was founded in 2015 and is headquartered in Palo Alto, California. | $304M / Series D / Oct 26, 2021 | |
Opentrons
|
OpenTrons is a developer of a pipetting robot technology designed to automate experiments. The company's technology is automated laboratory equipment that automates experiments by using Python language, enabling scientific researchers to make the process faster and less tiresome. | $10M / Seed / Mar 27, 2018 |
Co-Investors
About Israel Biotech Fund
Israel Biotech Fund – Building the future of Israeli BiotechIsrael Biotech Fund seeks high value returns by identifying and maximizing the success of therapeutic assets of Israel-based biotech companies.Based in Rehovot, Israel’s main Biotech hub, we invest exclusively in Biotech companies developing drugs at or near clinical stages.Ourpartners include two top-tier international pharmaceuticals companies, institutional investors, family offices and high net worth individuals.Our key asset is a unique team of 25 Venture Advisors, comprised of renowned industry leaders and professionals who, together with the fund’s managing partners, provide our portfolio companies with hands-on guidance and support.We don’t just invest in promising companies – we have the ability, experience and network required to identify the best opportunities and partner with our portfolio companies to help them go the distance.We provide our portfolio companies with the necessary resources for long-term sustainable growth. This approach enhances their value and the investor’s long-term capital appreciation, while strengthening Israel’s Biotech industry which increases investment opportunities.The biotechnology industry in Israel is growing with enormous potential and we are determined to realize its full potential and real value.
Israel Biotech Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ido Zairi
Co-Founder and Managing Partner
|
|||
Yuval Cabilly
Co-Founder and General Partner
|
|||
David Sidransky
Co-Founder and General Partner
|
|||
|
Jeffrey B. Kindler
Fund Advisor
|
|||
Jonathan Fassberg
Fund Advisor
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Jeffrey B. Kindler invest in?
Jeffrey B. Kindler invests primarily in Health Care, Medical Device and Clinical Trials startups, most often at Seed and Series D stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Jeffrey B. Kindler last invest?
The most recent investment recorded for Jeffrey B. Kindler closed in Aug 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
